Core Viewpoint - BeiGene's stock experienced a slight decline of 0.73% on March 31, with a trading volume of 738 million yuan, indicating a low financing balance relative to its market value [1] Financing Summary - On March 31, BeiGene had a financing buy amount of 63.91 million yuan and a financing repayment of 50.01 million yuan, resulting in a net financing purchase of 13.91 million yuan [1] - The total financing and securities balance for BeiGene reached 855 million yuan, with the financing balance at 836 million yuan, accounting for 3.11% of the circulating market value, which is below the 30th percentile level over the past year [1] Securities Lending Summary - On March 31, BeiGene repaid 4,026 shares in securities lending and sold 2,838 shares, with the selling amount calculated at 662,900 yuan [1] - The remaining securities lending volume was 79,400 shares, with a balance of 18.56 million yuan, exceeding the 90th percentile level over the past year, indicating a high level [1] Company Overview - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is located in Changping District, Beijing, and focuses on the research, development, production, and commercialization of innovative drugs [1] - The company's main revenue sources are 99.10% from drug sales and 0.90% from collaboration arrangements [1] Shareholder Information - As of September 30, 2025, BeiGene had 36,200 shareholders, an increase of 55.33% from the previous period, while the average circulating shares per person decreased by 35.79% to 3,195 shares [2] - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion yuan, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion yuan, up 130.88% year-on-year [2] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [2]

Core Viewpoint - Six companies in the Sci-Tech Innovation Board's growth tier have turned profitable in 2025 and will be removed from this tier, marking a significant milestone for these previously unprofitable firms [1][3]. Group 1: Company Performance - Cambrian (688256) reported a revenue of 6.497 billion and a net profit of 2.059 billion in 2025 [1]. - BeiGene (688235) achieved a revenue of 38.2 billion and a net profit of 1.422 billion, reflecting a 40.4% increase in total revenue compared to the previous year [3][5]. - Orbbec (688322) generated a revenue of 941 million and a net profit of 127 million in 2025 [4][6]. - Jikong Electric (688280) reported a revenue of 2.726 billion and a net profit of 162 million [6]. - North Chip Life (688712) achieved a revenue of 542 million and a net profit of 81 million [8]. - Innovent Biologics (688428) projected a revenue of approximately 2.365 billion and a net profit of around 633 million for 2025, although it did not release a performance report by the specified date [9]. Group 2: Growth Tier Overview - The Sci-Tech Innovation Board's growth tier was established to support technology companies that are not profitable at the time of listing but have significant technological breakthroughs and commercial potential [1]. - As of March 6, 2025, there are 39 companies in the growth tier, with 32 existing and 7 newly registered [1].

Group 1 - The core point of the news is that BeiGene's stock has experienced a decline of 10.47% over the past four days, with a current price of 237.87 CNY per share and a market capitalization of 366.48 billion CNY [1] - BeiGene was founded on October 28, 2010, and went public on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative drugs [1] - The main revenue composition of BeiGene is derived from drug sales, accounting for 99.10%, while collaboration revenue constitutes 0.90% [1] Group 2 - Red土 Innovation Fund has a significant holding in BeiGene, with 37,400 shares in its Red土 Innovation Healthcare Stock A fund, representing 3.79% of the fund's net value [2] - The fund has incurred a floating loss of approximately 48,530 CNY today and a total floating loss of 109,770 CNY during the four-day decline [2] - The Red土 Innovation Healthcare Stock A fund was established on October 20, 2020, with a current size of 234 million CNY and a year-to-date return of 5.66% [2]

Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene was established on October 28, 2010, and went public on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - Morgan Stanley's fund holds a significant position in BeiGene, with the Morgan Stanley Health Industry Mixed A Fund (002708) maintaining 231,800 shares, unchanged from the previous period, representing 4.12% of the fund's net value [2] - The Morgan Stanley Health Industry Mixed A Fund has a total size of 1.423 billion CNY and has experienced a loss of 0.47% this year, ranking 8462 out of 8887 in its category, while its one-year return is 0.89%, ranking 7892 out of 8134 [2] Group 3 - The fund manager of the Morgan Stanley Health Industry Mixed A Fund is Wang Dapeng, who has been in the position for 11 years and 39 days, with the fund's total asset size at 1.997 billion CNY. The best return during his tenure is 70.7%, while the worst return is -50.91% [3]

Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene, established on October 28, 2010, is located in Beijing and specializes in the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - From the perspective of major fund holdings, CITIC Prudential Fund has a significant position in BeiGene, holding 11,900 shares in its CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A, which accounts for 1.99% of the fund's net value, ranking it as the tenth largest holding [2] - The CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A was established on January 1, 2021, with a current size of 147 million CNY, and has reported a year-to-date return of 1.77% and a one-year return of 16.18% [2] - The fund manager, Huang Zhi, has been in the position for 7 years and 219 days, overseeing assets totaling 4.418 billion CNY, with the best fund return during his tenure being 146.63% and the worst being -26.08% [2]

Group 1 - The core viewpoint of the news is that BeiGene's stock has increased by 5.08%, reaching a price of 291.00 CNY per share, with a trading volume of 5.91 billion CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 448.34 billion CNY [1] - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is primarily engaged in the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - From the perspective of fund holdings, one fund under Huatai-PineBridge has a significant position in BeiGene, holding 16,700 shares, which accounts for 2.36% of the fund's net value, making it the seventh-largest holding [2] - The Sci-Tech Innovation Index (588880) has reduced its holdings by 3,149 shares in the fourth quarter, with a current estimated floating profit of approximately 235,600 CNY [2] - The Sci-Tech Innovation Index fund, established on November 8, 2023, has a latest scale of 191 million CNY, with a year-to-date return of 11.76% and a one-year return of 62.02%, ranking 357 out of 4,295 in its category [2]

Core Viewpoint - The company, BeiGene, is a leading global innovator in cancer treatment, focusing on developing innovative anti-tumor drugs to enhance accessibility and affordability for cancer patients [2]. Financial Performance - For the period from January to September 2025, BeiGene achieved a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21% [6]. - The net profit attributable to the parent company was 1.139 billion yuan, showing a significant year-on-year increase of 130.88% [6]. Market Activity - On February 3, BeiGene's stock rose by 1.64%, with a trading volume of 651 million yuan and a turnover rate of 2.08%, bringing the total market capitalization to 421.221 billion yuan [1]. - The stock has seen a net outflow of 17.2595 million yuan from major investors today, with a ranking of 145 out of 158 in the industry [3][4]. Shareholder Information - As of September 30, 2025, the number of shareholders for BeiGene increased to 36,200, a rise of 55.33% compared to the previous period [6]. - The average number of tradable shares per shareholder decreased by 35.79% to 3,195 shares [6]. Institutional Holdings - Among the top ten circulating shareholders, China Europe Medical Health Mixed A holds 4.6788 million shares, a decrease of 146,600 shares from the previous period [7]. - Hong Kong Central Clearing Limited is a new shareholder with 3.1565 million shares [7].

Group 1 - The core viewpoint of the news is that BeiGene's stock performance and financing activities indicate a mixed sentiment among investors, with a notable increase in shareholder numbers and significant revenue growth reported [1][2]. Group 2 - On January 22, BeiGene's stock fell by 1.77%, with a trading volume of 583 million yuan. The financing buy-in amount was 51.87 million yuan, while the financing repayment was 43.98 million yuan, resulting in a net financing buy of 7.89 million yuan. The total financing and securities balance reached 871 million yuan [1]. - As of January 22, BeiGene's financing balance was 864 million yuan, accounting for 2.61% of its market capitalization, which is below the 40th percentile level over the past year, indicating a low financing level [1]. - On the same day, BeiGene's securities lending saw a repayment of 2,694 shares and a sale of 32 shares, with a selling amount of 9,193.60 yuan. The securities lending balance was 727.21 million yuan, exceeding the 50th percentile level over the past year, indicating a high level of securities lending [1]. - As of September 30, BeiGene had 36,200 shareholders, an increase of 55.33% from the previous period, while the average number of circulating shares per person decreased by 35.79% to 3,195 shares [2]. - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21%, and a net profit attributable to shareholders of 1.139 billion yuan, reflecting a significant increase of 130.88% [2]. - Among the top ten circulating shareholders as of September 30, 2025, notable changes included a decrease in holdings by several funds, while new shareholders entered the list, indicating a shift in institutional interest [2].

Core Viewpoint - The company, BeiGene, is a leading global innovator in cancer treatment, focusing on developing innovative anti-tumor drugs to enhance accessibility and affordability for cancer patients [2]. Financial Performance - For the period from January to September 2025, BeiGene achieved a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21% [7]. - The net profit attributable to the parent company was 1.139 billion yuan, showing a significant year-on-year increase of 130.88% [7]. - As of September 30, 2024, overseas revenue accounted for 62.85% of the total revenue, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On December 31, BeiGene's stock price decreased by 1.25%, with a trading volume of 358 million yuan and a turnover rate of 1.15%, resulting in a total market capitalization of 413.826 billion yuan [1]. - The main capital flow showed a net outflow of 54.6938 million yuan for the day, with a continuous reduction in main capital over the past three days [4][5]. Shareholder Information - As of September 30, 2025, the number of shareholders for BeiGene was 36,200, an increase of 55.33% compared to the previous period [7]. - The average number of tradable shares per shareholder was 3,195, which decreased by 35.79% from the previous period [7]. - Notable changes in institutional holdings include a decrease in shares held by major shareholders such as China Europe Medical Health Mixed A and a new entry by Hong Kong Central Clearing Limited [8]. Technical Analysis - The average trading cost of BeiGene's shares is 287.32 yuan, with recent reductions in holdings, although the pace of reduction has slowed [6]. - The current stock price is near a support level of 267.83 yuan, which is critical for potential rebound; a drop below this level may trigger a downward trend [6].

Group 1 - The core viewpoint of the news is that BeiGene has shown significant financial performance with a notable increase in revenue and net profit, alongside active trading activity in its stock [2]. - As of December 23, BeiGene's stock price increased by 0.92%, with a trading volume of 411 million yuan, indicating a healthy market interest [1]. - The financing data reveals that on December 23, BeiGene had a net financing outflow of 10.19 million yuan, with a total financing balance of 1 billion yuan, which is 3.12% of its market capitalization [1]. Group 2 - For the period from January to September 2025, BeiGene achieved a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21%, while the net profit attributable to shareholders was 1.139 billion yuan, up 130.88% year-on-year [2]. - The number of shareholders for BeiGene increased to 36,200, a rise of 55.33%, while the average number of circulating shares per person decreased by 35.79% to 3,195 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by several funds, while new shareholders have entered, indicating a shift in institutional interest [2].